A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies

Journal of the American College of Cardiology

Volumn 69, Issue 6, 2017, Pages 692-711

  Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aortic stenosis; cardiovascular disease; genome wide association studies; therapy

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; LIPOPROTEIN A; MESSENGER RNA; MIPOMERSEN; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PITAVASTATIN; PLASMIN; PLASMINOGEN; PRAVASTATIN; ROSUVASTATIN;

AORTA VALVE STENOSIS; CALCIFIC AORTA VALVE STENOSIS; CARDIOVASCULAR DISEASE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DISEASE COURSE; EAST ASIAN; HISPANIC; HUMAN; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SOUTH ASIAN; STANDARDIZATION; CARDIOVASCULAR DISEASES; PHYSIOLOGY; PROGNOSIS;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); PROGNOSIS; RISK FACTORS;

EID: 85011556752     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.11.042     Document Type: Review

References (78)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
2. 2 AIM-HIGH-Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
3. 3 Barter, P.J., Rye, K.A., New era of lipid-lowering drugs. Pharmacol Rev 68 (2016), 458–475.
4. 4 Schmidt, K., Noureen, A., Kronenberg, F., et al. Structure, function, and genetics of lipoprotein (a). J Lipid Res 57 (2016), 1339–1359.
5. 5 Marcovina, S.M., Albers, J.J., Gabel, B., et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41 (1995), 246–255.
6. 6 Kronenberg, F., Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther 30 (2016), 87–100.
7. 7 Kronenberg, F., Utermann, G., Lipoprotein(a): resurrected by genetics. J Intern Med 273 (2013), 6–30.
8. 8 Steinberg, D., Witztum, J.L., Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 30 (2010), 2311–2316.
9. 9 Spence, J.D., Koschinsky, M.L., Mechanisms of lipoprotein(a) pathogenicity. Arterioscler Thromb Vasc Biol 32 (2012), 1550–1551.
10. 10 Bergmark, C., Dewan, A., Orsoni, A., et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49 (2008), 2230–2239.
11. 11 Leibundgut, G., Scipione, C., Yin, H., et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 54 (2013), 2815–2830.
12. 12 van der Valk, F.M., Bekkering, S., Kroon, J., et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134 (2016), 611–624.
13. 13 Kiechl, S., Willeit, J., Mayr, M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007), 1788–1795.
14. 14 Tsimikas, S., Mallat, Z., Talmud, P.J., et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 56 (2010), 946–955.
15. 15 Tsimikas, S., Willeit, P., Willeit, J., et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 60 (2012), 2218–2229.
16. 16 Bertoia, M.L., Pai, J.K., Lee, J.H., et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 61 (2013), 2169–2179.
17. 17 Tsimikas, S., Duff, G.W., Berger, P.B., et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol 63 (2014), 1724–1734.
18. 18 Byun, Y.S., Lee, J.H., Arsenault, B.J., et al., TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65 (2015), 1286–1295.
19. 19 Capoulade, R., Chan, K.L., Yeang, C., et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 66 (2015), 1236–1246.
20. 20 Nsaibia, M.J., Mahmut, A., Boulanger, M.C., et al. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. J Intern Med 280 (2016), 509–517.
21. 21 Scipione, C.A., Sayegh, S.E., Romagnuolo, R., et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res 56 (2015), 2273–2285.
22. 22 Wiesner, P., Tafelmeier, M., Chittka, D., et al. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res 54 (2013), 1877–1883.
23. 23 van Dijk, R.A., Kolodgie, F., Ravandi, A., et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 53 (2012), 2773–2790.
24. 24 Ravandi, A., Leibundgut, G., Hung, M.Y., et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol 63 (2014), 1961–1971.
25. 25 Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009), 412–423.
26. 26 Kamstrup, P.R., Tybjærg-Hansen, A., Nordestgaard, B.G., Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 61 (2013), 1146–1156.
27. 27 Clarke, R., Peden, J.F., Hopewell, J.C., et al., PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009), 2518–2528.
28. 28 CARDIoGRAMplusC4D Consortium, Deloukas, P., Kanoni, S., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45 (2013), 25–33.
29. 29 Tsimikas, S., Viney, N.J., Hughes, S.G., et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.
30. 30 Kamstrup, P.R., Tybjærg-Hansen, A., Steffensen, R., et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009), 2331–2339.
31. 31 Kyriakou, T., Seedorf, U., Goel, A., et al., PROCARDIS Consortium. A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk. Arterioscler Thromb Vasc Biol 34 (2014), 2095–2099.
32. 32 Lim, E.T., Würtz, P., Havulinna, A.S., et al. Sequencing Initiative Suomi (SISu) Project distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet, 10, 2014, e1004494.
33. 33 Yeang, C., Wilkinson, M.J., Tsimikas, S., Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Curr Opin Cardiol 31 (2016), 440–450.
34. 34 Thanassoulis, G., Campbell, C.Y., Owens, D.S., et al., CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368 (2013), 503–512.
35. 35 Kamstrup, P.R., Tybjærg-Hansen, A., Nordestgaard, B.G., Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63 (2014), 470–477.
36. 36 Arsenault, B.J., Boekholdt, S.M., Dubé, M.P., et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 7 (2014), 304–310.
37. 37 Vongpromek, R., Bos, S., Ten Kate, G.J., et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med 278 (2015), 166–173.
38. 38 Chan, K.L., Teo, K., Dumesnil, J.G., et al., ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation 121 (2010), 306–314.
39. 39 Bouchareb, R., Mahmut, A., Nsaibia, M.J., et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 132 (2015), 677–690.
40. 40 Marcovina, S.M., Albers, J.J., Lipoprotein (a) measurements for clinical application. J Lipid Res 57 (2016), 526–537.
41. 41 Verbeek, R., Boekholdt, S.M., Stoekenbroek, R.M., et al. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 57 (2016), 697–705.
42. 42 Kostner, G.M., Avogaro, P., Cazzolato, G., et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38 (1981), 51–61.
43. 43 Nordestgaard, B.G., Chapman, M.J., Ray, K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31 (2010), 2844–2853.
44. 44 Khera, A.V., Everett, B.M., Caulfield, M.P., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 129 (2014), 635–642.
45. 45 Albers, J.J., Slee, A., O'Brien, K.D., et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 62 (2013), 1575–1579.
46. 46 Anderson, T.J., Grégoire, J., Pearson, G.J., et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 32 (2016), 1263–1282.
47. 47 Willeit, P., Kiechl, S., Kronenberg, F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860 erratum J Am Coll Cardiol 2016;67:737.
48. 48 Davidson, M.H., Ballantyne, C.M., Jacobson, T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 5 (2011), 338–367.
49. 49 Catapano, A.L., Graham, I., De Backer, G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 37 (2016), 2999–3058.
50. 50 Deo, R.C., Wilson, J.G., Xing, C., et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One, 6, 2011, e14581.
51. 51 Tsimikas, S., Clopton, P., Brilakis, E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 119 (2009), 1711–1719.
52. 52 Nikpay, M., Goel, A., Won, H.H., et al., CARDIoGRAMplusC4D Consortium. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47 (2015), 1121–1130.
53. 53 Virani, S.S., Brautbar, A., Davis, B.C., et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 125 (2012), 241–249.
54. 54 Gambhir, J.K., Kaur, H., Prabhu, K.M., et al. Association between lipoprotein(a) levels, apo(a) isoforms and family history of premature CAD in young Asian Indians. Clin Biochem 41 (2008), 453–458.
55. 55 Cai, D.P., He, Y.M., Yang, X.J., et al. Lipoprotein (a) is a risk factor for coronary artery disease in Chinese Han ethnic population modified by some traditional risk factors: a cross-sectional study of 3462 cases and 6125 controls. Clin Chim Acta 451 (2015), 278–286.
56. 56 Lanktree, M.B., Anand, S.S., Yusuf, S., et al., SHARE Investigators. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 3 (2010), 39–46.
57. 57 Guan, W., Cao, J., Steffen, B.T., et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 35 (2015), 996–1001.
58. 58 Nestel, P.J., Barnes, E.H., Tonkin, A.M., et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 33 (2013), 2902–2908.
59. 59 Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al., IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
60. 60 Yeang, C., Hung, M.Y., Byun, Y.S., et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol 10 (2016), 594–603.
61. 61 Yeang, C., Witztum, J.L., Tsimikas, S., ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 26 (2015), 169–178.
62. 62 Viney, N.J., van Capelleveen, J.C., Geary, R.S., et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388 (2016), 2239–2253.
63. 63 Moriarty, P.M., Hemphill, L., Lipoprotein apheresis. Endocrinol Metab Clin North Am 45 (2016), 39–54.
64. 64 Roeseler, E., Julius, U., Heigl, F., et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol 36 (2016), 2019–2027.
65. 65 Shlipak, M.G., Simon, J.A., Vittinghoff, E., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283 (2000), 1845–1852.
66. 66 Duell, P.B., Santos, R.D., Kirwan, B.A., et al. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol 10 (2016), 1011–1021.
67. 67 Hossne, N.A., Cruz, E., Buffolo, E., et al. Long-term and sustained therapeutic results of a specific promonocyte cell formulation in refractory angina: ReACT (Refractory Angina Cell Therapy) clinical update and cost-effective analysis. Cell Transplant 24 (2015), 955–970.
68. 68 Raal, F.J., Giugliano, R.P., Sabatine, M.S., et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63 (2014), 1278–1288.
69. 69 Raal, F.J., Stein, E.A., Dufour, R., et al., RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 331–340.
70. 70 Boffa, M.B., Koschinsky, M.L., Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?. J Lipid Res 57 (2016), 745–757.
71. 71 Kamstrup, P.R., Tybjærg-Hansen, A., Nordestgaard, B.G., Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 32 (2012), 1732–1741.
72. 72 Helgadottir, A., Gretarsdottir, S., Thorleifsson, G., et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 60 (2012), 722–729.
73. 73 Chasman, D.I., Shiffman, D., Zee, R.Y., et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 203 (2009), 371–376.
74. 74 Crooke, S.T., Geary, R.S., Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 76 (2013), 269–276.
75. 75 Merki, E., Graham, M.J., Mullick, A.E., et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118 (2008), 743–753.
76. 76 Santos, R.D., Raal, F.J., Catapano, A.L., et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol 35 (2015), 689–699.
77. 77 Merki, E., Graham, M., Taleb, A., et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 57 (2011), 1611–1621.
78. 78 Graham, M.J., Viney, N., Crooke, R.M., et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res 57 (2016), 340–351.